Wang et al. [21] demonstrated that rapamycin attenuates murine hepatic steatosis by reducing CD36 expression via inhibiting transcriptional efficiency, offering a potential mechanism of reducing CD36 expression in vivo[21]. This evidence concerns the gene CD36 and fatty liver disease.